GlassScriptPhysician profile
Parameswaran Hariharan
NPI 1720084460
$1,858.39
in general payments reported to CMS, 2019-2025
26 companies · $367 in 2025
The $367 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $889 · 2020: $145 · 2022: $184 · 2023: $123 · 2024: $151 · 2025: $367.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $641.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $641.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $195.56 | 2019-2025 | |
| Boston Scientific Corporation | $194.58 | 2019-2025 | Watchman Access System |
| Abbvie INC. | $193.39 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $153.50 | 2019-2025 | Farxiga, Airsupra |
| Amgen INC. | $113.70 | 2019-2022 | |
| Astellas Pharma US INC | $111.88 | 2019 | |
| Imperative Care, INC | $101.71 | 2023 | Prodigy Catheter |
| Novo Nordisk INC | $95.54 | 2019-2025 | Rybelsus, Ozempic |
| Lilly USA, LLC | $84.99 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $74.87 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $68.31 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $65.86 | 2019-2024 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $62.16 | 2019-2024 | Xifaxan, Trulance |
| Merck Sharp & Dohme LLC | $45.90 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $44.93 | 2019-2024 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $37.48 | 2019-2024 | Eliquis |
| Kowa Pharmaceuticals America, INC. | $32.81 | 2019 | |
| Glaxosmithkline, LLC. | $30.64 | 2019-2025 | Trelegy Ellipta |
| Amarin Pharma, INC. | $27.12 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.63 | 2019 | |
| Paratek Pharmaceuticals, INC. | $23.04 | 2024 | Nuzyra |
| Phathom Pharmaceuticals, INC. | $19.99 | 2024 | Voquezna |
| Exact Sciences Corporation | $17.63 | 2025 | The Cologuard Plus Collection Kit |
| Sumitomo Pharma America, INC. | $13.87 | 2025 | Gemtesa |
| Vifor Pharma, INC. | $13.42 | 2019 | |
| Sanofi Pasteur INC. | $11.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Parameswaran Hariharan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.